Celldex Therapeutics shares owned by Ubs Global Asset Management Americas
Quarter-by-quarter ownership of Celldex Therapeutics (CLDX) shares owned by Ubs Global Asset Management Americas
from 13F filings
Historical chart of Ubs Global Asset Management Americas investment in Celldex Therapeutics
Tip: Access up to 7 years of quarterly data
All positions including Celldex Therapeutics held by Ubs Global Asset Management Americas consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Quarterly reported holdings in Celldex Therapeutics by Ubs Global Asset Management Americas
| Quarter filed | Position value | Share count | Share price at filing |
|---|---|---|---|
| 2023-12-31 | $1.4M | 35k | 39.66 |
| 2023-09-30 | $960k | 35k | 27.52 |
| 2023-06-30 | $1.1M | 32k | 35.98 |
| 2023-03-31 | $1.1M | 32k | 35.98 |
| 2022-12-31 | $1.3M | 30k | 44.57 |
| 2022-09-30 | $850k | 30k | 28.11 |
| 2022-06-30 | $794k | 29k | 26.96 |
| 2022-03-31 | $1.1M | 33k | 34.06 |
| 2021-12-31 | $1.3M | 33k | 38.64 |
| 2021-09-30 | $2.0M | 36k | 53.99 |
| 2021-06-30 | $1.1M | 34k | 33.44 |
| 2021-03-31 | $729k | 35k | 20.60 |
| 2020-12-31 | $596k | 34k | 17.52 |
More positions owned by Ubs Global Asset Management Americas
View all positions for Ubs Global Asset Management Americas